This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ReNeuron Group Valuation

Is RQE1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RQE1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RQE1's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RQE1's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RQE1?

Key metric: As RQE1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RQE1. This is calculated by dividing RQE1's market cap by their current revenue.
What is RQE1's PS Ratio?
PS Ratio	7.7x
Sales	UK£249.00k
Market Cap	UK£1.93m

RQE1 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does RQE1's PS Ratio compare to its peers?

The above table shows the PS ratio for RQE1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	72.8x
CNW co.don	0.7x	n/a	€6.5m
SBH Sangui Biotech International	3.8x	n/a	€419.8k
BPXA Bellicum Pharmaceuticals	0.5x	n/a	€772.4k
T5O bioXXmed	286x	n/a	€1.4m
RQE1 ReNeuron Group	7.7x	n/a	€1.9m

Price-To-Sales vs Peers: RQE1 is expensive based on its Price-To-Sales Ratio (7.7x) compared to the peer average (3x).

Price to Sales Ratio vs Industry

How does RQE1's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
CNW co.don	0.7x	n/a	US$6.97m
V9Z Aceragen	0.4x	n/a	US$3.12m
PA8 Paion	0.2x	30.2%	US$2.78m
V9Z Aceragen	0.3x	-161.8%	US$2.18m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: RQE1 is good value based on its Price-To-Sales Ratio (7.7x) compared to the European Biotechs industry average (9.7x).

Price to Sales Ratio vs Fair Ratio

What is RQE1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RQE1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	7.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate RQE1's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

0.6%

4.7%

Fortrea Holdings

US$1.8b

A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.

K67

US$18.40

-1.6%

-38.3%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.29

-1.8%

0.2%